Corcept Therapeutics Incorporated (CORT) — Cash Flow Quality Index
Corcept Therapeutics Incorporated (CORT) has a Cash Flow Quality Index of 0.39x as of December 2025. Operating cash flow of $38.45 Million is below net income of $98.17 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Corcept Therapeutics Incorporated (CORT) long-term investment share to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Corcept Therapeutics Incorporated Cash Flow Quality Index (2016–2025)
Historical Cash Flow Quality Index for Corcept Therapeutics Incorporated across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CORT tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Corcept Therapeutics Incorporated (2016–2025)
Year-by-year earnings quality comparison for Corcept Therapeutics Incorporated. For live market cap and the full company financial profile, see CORT company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.45x | $142.00 Million | $98.17 Million | ▲ +3.1% |
| 2024 | 1.40x | $198.07 Million | $141.21 Million | ▲ +17.2% |
| 2023 | 1.20x | $127.04 Million | $106.14 Million | ▲ +0.9% |
| 2022 | 1.19x | $120.32 Million | $101.42 Million | ▼ -20.5% |
| 2021 | 1.49x | $167.89 Million | $112.51 Million | ▲ +4.1% |
| 2020 | 1.43x | $151.97 Million | $106.01 Million | ▼ -0.8% |
| 2019 | 1.45x | $136.12 Million | $94.18 Million | ▼ -5.8% |
| 2018 | 1.53x | $115.67 Million | $75.41 Million | ▲ +225.0% |
| 2017 | 0.47x | $60.94 Million | $129.12 Million | ▼ -79.1% |
| 2016 | 2.26x | $18.39 Million | $8.14 Million | — |